Filtered By:
Source: Diabetes, Obesity and Metabolism
Condition: Obesity
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 82 results found since Jan 2013.
Cardiovascular events and all ‐cause mortality associated with sulfonylureas compared to other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data
ConclusionThis meta‐analysis shows an association between sulfonylurea therapy and a higher risk of major cardiovascular disease‐related events compared to other antihyperglycaemic drugs. Results of ongoing RCTs, which should be available in 2018, will provide definitive results on the risk of cardiovascular events and all‐cause mortality associated with sulfonylureas versus other antihyperglycaemic drugs.
Source: Diabetes, Obesity and Metabolism - October 31, 2016 Category: Endocrinology Authors: Steve Bain, Eric Druyts, Chakrapani Balijepalli, Carl A Baxter, Craig Currie, Romita Das, Richard Donnelly, Kamlesh Khunti, Haya Langerman, Paul Leigh, Gaye Siliman, Kristian Thorlund, Kabirraaj Toor, Jiten Vora, Edward J Mills Tags: Original Article Source Type: research
Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy
ConclusionsThe combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy vary considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - August 11, 2016 Category: Endocrinology Authors: N. G. C. Sande, J. A. N. Dorresteijn, F. L. J. Visseren, J. P. Dwyer, P. J. Blankestijn, Y. Graaf, H. L. J. Heerspink Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular safety of glucose ‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
ConclusionsThis nationwide observational study showed that second‐line treatment with TZD and DPP‐4 inhibitor as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - July 18, 2016 Category: Endocrinology Authors: Nils Ekstr öm, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta ‐analysis of data from randomized placebo‐controlled trials
ConclusionsIn a meta‐analysis of data from 8 randomized trials involving 11292 patients with T2DM at low/medium or high CV risk, empagliflozin was associated with a reduced risk of 4‐point MACE and 3‐point MACE compared with placebo.
Source: Diabetes, Obesity and Metabolism - July 3, 2016 Category: Endocrinology Authors: A. Salsali, G. Kim, H. J. Woerle, U. C. Broedl, S. Hantel Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
ConclusionsIn a meta‐analysis of data from 8 randomized trials involving 11292 patients with T2DM at low/medium or high CV risk, empagliflozin was associated with a reduced risk of 4‐point MACE and 3‐point MACE compared with placebo.
Source: Diabetes, Obesity and Metabolism - June 30, 2016 Category: Endocrinology Authors: A. Salsali, G. Kim, H. J. Woerle, U. C. Broedl, S. Hantel Tags: ORIGINAL ARTICLE Source Type: research
Comparative risk of major cardiovascular events associated with second ‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks of major cardiovascular disease or cardiovascular death compared with sulphonylurea add‐on treatment to metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4 inhibitor add‐on therapies.
Source: Diabetes, Obesity and Metabolism - June 29, 2016 Category: Endocrinology Authors: S. S. Zghebi, D. T. Steinke, M. K. Rutter, R. A. Emsley, D. M. Ashcroft Tags: ORIGINAL ARTICLE Source Type: research
Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy
Conclusions The combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy varies considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - June 23, 2016 Category: Endocrinology Authors: Nicolette G.C. van der Sande, Jannick A.N. Dorresteijn, Frank. L.J. Visseren, Jamie P. Dwyer, Peter J. Blankestijn, Yolanda van der Graaf, Hiddo L. Heerspink Tags: ORIGINAL ARTICLE Source Type: research
Risk prediction of major complications in individuals with diabetes: the Atherosclerosis Risk in Communities Study
ConclusionsThese biomarkers, particularly those of kidney filtration, may help distinguish between people at low versus high risk of long‐term major complications.
Source: Diabetes, Obesity and Metabolism - June 13, 2016 Category: Endocrinology Authors: C. M. Parrinello, K. Matsushita, M. Woodward, L. E. Wagenknecht, J. Coresh, E. Selvin Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular Safety of Glucose‐Lowering Agents as Add‐on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR)
Conclusions: This nationwide observational study showed that second‐line treatment with TZD and DPP‐4i as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - May 31, 2016 Category: Endocrinology Authors: Nils Ekström, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research
Comparative risk of major cardiovascular events associated with second‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks for major cardiovascular disease or cardiovascular death compared to sulphonylurea combination with metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4i add‐on therapies.
Source: Diabetes, Obesity and Metabolism - May 12, 2016 Category: Endocrinology Authors: Salwa S Zghebi, Douglas T Steinke, Martin K Rutter, Richard A Emsley, Darren M Ashcroft Tags: ORIGINAL ARTICLE Source Type: research
Risk prediction of major complications in persons with diabetes: The Atherosclerosis Risk in Communities Study
ConclusionsThese biomarkers, particularly those of kidney filtration, may help distinguish between persons at low versus high risk of long‐term major complications.
Source: Diabetes, Obesity and Metabolism - May 9, 2016 Category: Endocrinology Authors: Christina M. Parrinello, Kunihiro Matsushita, Mark Woodward, Lynne E. Wagenknecht, Josef Coresh, Elizabeth Selvin Tags: ORIGINAL ARTICLE Source Type: research
Comparative cardiovascular safety of glucagon ‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - May 1, 2016 Category: Endocrinology Authors: E. Patorno, B. M. Everett, A. B. Goldfine, R. J. Glynn, J. Liu, C. Gopalakrishnan, S. C. Kim Tags: ORIGINAL ARTICLE Source Type: research
Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research
Comparative Cardiovascular Safety of Glucagon‐Like Peptide‐1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RA versus other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - March 23, 2016 Category: Endocrinology Authors: Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, Jun Liu, Chandrasekar Gopalakrishnan, Seoyoung C. Kim Tags: Original Article Source Type: research
Gliptin‐mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon‐like peptide‐1 receptor
Gliptins are anti‐type 2 diabetes (T2D) drugs that regulate glycaemia by preventing endogenous glucagon‐like peptide‐1 (GLP‐1) degradation. Chronically administered gliptins before experimental stroke can also induce neuroprotection, and this effect is potentially relevant for reducing brain damage in patients with T2D and high risk of stroke. It is not known, however, whether acute gliptin treatment after stroke (mimicking a post‐hospitalization treatment) is neuroprotective or whether gliptin‐mediated neuroprotection occurs via GLP‐1‐receptor (GLP‐1R) activation. To answer these two questions, wild‐ty...
Source: Diabetes, Obesity and Metabolism - March 17, 2016 Category: Endocrinology Authors: V. Darsalia, M. Larsson, G. Lietzau, D. Nathanson, T. Nyström, T. Klein, C. Patrone Tags: RESEARCH LETTER Source Type: research
